Lyell Immunopharma stock: financing supports ronde-cel BLA plan

Lyell Immunopharma announced an approximately 80 million US dollar private placement on Wednesday, November 4, 2026, while also reporting updated clinical results for its investigational CAR T-cell therapy ronde-cel. In its company release, Lyell said it agreed to sell 7,428,040 common shares at 10.77 US dollars per share. The transaction is intended to extend the company's cash runway into 2028.

Ronde-Cel Moves Toward Key Milestones

Lyell said ronde-cel achieved a 91 percent overall response rate and a 77 percent complete response rate among 44 efficacy-evaluable patients in the third-line or later PiNACLE trial for relapsed or refractory large B-cell lymphoma. Median progression-free survival and median duration of complete response had not been reached in the reported analysis.

The company expects to present additional results from more than 80 patients at the American Society of Hematology annual meeting in December. Lyell said the full pivotal PiNACLE dataset is expected in mid-2027, followed by a planned Biologics License Application submission to the US Food and Drug Administration in the second half of 2027.

Funding Intensifies Competitive Test

The financing gives Lyell additional resources for clinical development, but the program remains dependent on pivotal trial outcomes and regulatory progress. GenomeWeb reported that Lyell's PiNACLE-H2H study compares ronde-cel with Bristol Myers Squibb's Breyanzi and Gilead Sciences' Yescarta, two approved CD19-directed CAR T-cell therapies.

Lyell's Business and Competition

Lyell Immunopharma is a South San Francisco, California-based clinical-stage biotechnology company developing next-generation CAR T-cell therapies for cancer. Its pipeline covers ronde-cel for relapsed or refractory large B-cell lymphoma and LYL273 for metastatic colorectal cancer, alongside its manufacturing capabilities. Lyell is a late-stage clinical challenger to commercial cell-therapy groups including Bristol Myers Squibb and Gilead Sciences, which already market competing CAR T-cell products in lymphoma. Its investment case therefore remains tied to clinical execution, manufacturing scale-up and regulatory delivery rather than current product sales.

The S&P 500 provides the broader US equity-market backdrop for biotech investors; see current market coverage.

See more news and analyses on Lyell Immunopharma stock.